SCHEMBL59397

SCHEMBL59397

C=COCC(CC)S(=O)(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL790112 0.76 RECQL (0.32)
SCHEMBL5057275 0.76 TSHR (0.53)
SCHEMBL28604834 0.74 RECQL (0.31)
SCHEMBL15868130 0.72 CA1 (0.33)
SCHEMBL19154262 0.72 CA1 (0.32)
SCHEMBL3096305 0.72
SCHEMBL329520 0.72
SCHEMBL28552161 0.71
SCHEMBL11647729 0.71 HCAR2 (0.39)
SCHEMBL11698106 0.71 HCAR2 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078159-A1 NOVEL PD1-TARGETED IL-15 IMMUNOCYTOKINE and VITOKINE FUSIONS CUGENE INC (US) 2026-03-19 US disclosed
US-20250255938-A1 CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO THORNHILL THERAPEUTICS INC (US) 2025-08-14 US disclosed
US-20250242039-A1 TOXIN-DERIVED DELIVERY CONSTRUCTS THORNHILL THERAPEUTICS INC (US) 2025-07-31 US disclosed
EP-4583901-A1 NOVEL PD1-TARGETED IL-15 IMMUNOCYTOKINE AND VITOKINE FUSIONS Cugene Inc. (US) 2025-07-16 EP disclosed
EP-4584379-A1 NOVEL PD1-TARGETED IL-2 IMMUNOCYTOKINE AND VITOKINE FUSIONS Cugene Inc. (US) 2025-07-16 EP disclosed
CN-120152731-A Novel PD 1-targeted IL-15 immunocytokines and VitoKine fusions 科优基因公司 2025-06-13 CN disclosed
CN-120153079-A Novel PD 1-targeted IL-2 immunocytokines and VitoKine fusions 科优基因公司 2025-06-13 CN disclosed
CN-115087464-B Novel interleukin-15 (IL-15) fusion proteins and uses thereof 科优基因公司 2025-02-25 CN disclosed
EP-4461750-A2 NOVEL INTERLEUKIN-15 (IL-15) FUSION PROTEINS AND USES THEREOF Cugene Inc. (US) 2024-11-13 EP disclosed
US-20240299565-A1 TOXIN-DERIVED DELIVERY CONSTRUCTS APPLIED MOLECULAR TRANSPORT INC. 2024-09-12 US disclosed
US-20060205037-A1 Modified transferrin fusion proteins BIOREXIS PHARMACEUTICAL CORPORATION 2006-09-14 US disclosed
EP-1611093-A4 MODIFIED TRANSFERRIN FUSION PROTEINS BIOREXIS PHARMACEUTICAL CORP (US) 2006-06-28 EP disclosed
EP-1663278-A2 EPO MIMETIC PEPTIDES AND FUSION PROTEINS Biorexis Pharmaceutical Corporation (US) 2006-06-07 EP disclosed
WO-2006049983-A2 PEPTIDE YY MODIFIED TRANSFERRIN FUSION PROTEINS BIOREXIS PHARMACEUTICAL CORPORATION (US) 2006-05-11 WO disclosed
EP-1611093-A2 MODIFIED TRANSFERRIN FUSION PROTEINS Biorexis Pharmaceutical Corporation (US) 2006-01-04 EP disclosed
WO-2005021579-A2 EPO MIMETIC PEPTIDES AND FUSION PROTEINS BIOREXIS PHARMACEUTICAL CORPORATION (US) 2005-03-10 WO disclosed
WO-2004020405-A2 MODIFIED TRANSFERRIN FUSION PROTEINS BIOREXIS PHARMACEUTICAL CORPORATION (US) 2004-03-11 WO disclosed
WO-2004019872-A2 ORAL DELIVERY OF MODIFIED TRANSFERRIN FUSION PROTEINS BIOREXIS PHARMACEUTICAL CORPORATION (US) 2004-03-11 WO disclosed
US-6616944-B2 Active agent and polyol ester having biodegradable hydroxy carboxylic ester groups attached to backbone MEDINNOVA GESELLSCHAFT FUR MEDIZINSCHE INNOVATIONEN AUS ADKADEMISCHER FORSCHUNG MBH (DE) 2003-09-09 US disclosed
US-20010047074-A1 Self-assembling colloidal carriers for protein delivery NANOHALE MANAGEMENT LTD. (DE) 2001-11-29 US disclosed